These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26458165)

  • 41. Nutraceuticals in rodent models as potential treatments for human Inflammatory Bowel Disease.
    Ghattamaneni NKR; Panchal SK; Brown L
    Pharmacol Res; 2018 Jun; 132():99-107. PubMed ID: 29680446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives.
    Neurath MF
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Homing of immune cells: role in homeostasis and intestinal inflammation.
    Hart AL; Ng SC; Mann E; Al-Hassi HO; Bernardo D; Knight SC
    Inflamm Bowel Dis; 2010 Nov; 16(11):1969-77. PubMed ID: 20848507
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methyl jasmonate: a phytohormone with potential for the treatment of inflammatory bowel diseases.
    Besson JCF; de Carvalho Picoli C; Matioli G; Natali MRM
    J Pharm Pharmacol; 2018 Feb; 70(2):178-190. PubMed ID: 29072315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. From immunogenic mechanisms to novel therapeutic approaches in inflammatory bowel disease.
    Holtmann MH; Neurath MF
    Adv Exp Med Biol; 2006; 579():227-42. PubMed ID: 16620022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in inflammatory bowel diseases in children.
    Michail S; Ramsy M; Soliman E
    Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease.
    Uhlig HH
    Gut; 2013 Dec; 62(12):1795-805. PubMed ID: 24203055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New insights on fibrosis in Crohn's disease.
    Bailey JR; Whiting CV; Tarlton JF; Bland PW; Probert CS
    Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):497-9. PubMed ID: 23984996
    [No Abstract]   [Full Text] [Related]  

  • 50. Neuro-glial crosstalk in inflammatory bowel disease.
    Neunlist M; Van Landeghem L; Bourreille A; Savidge T
    J Intern Med; 2008 Jun; 263(6):577-83. PubMed ID: 18479256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
    Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab.
    Barrie A; Plevy S
    Gastroenterol Clin North Am; 2006 Dec; 35(4):883-93. PubMed ID: 17129819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crosstalk between the gut and the liver via susceptibility loci: Novel advances in inflammatory bowel disease and autoimmune liver disease.
    Li X; Shen J; Ran Z
    Clin Immunol; 2017 Feb; 175():115-123. PubMed ID: 27777084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current stage in inflammatory bowel disease: What is next?
    Gómez-Gómez GJ; Masedo Á; Yela C; Martínez-Montiel Mdel P; Casís B
    World J Gastroenterol; 2015 Oct; 21(40):11282-303. PubMed ID: 26525013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Complexity of alpha E beta 7 Blockade in Inflammatory Bowel Diseases.
    Smids C; Horjus Talabur Horje CS; van Wijk F; van Lochem EG
    J Crohns Colitis; 2017 Apr; 11(4):500-508. PubMed ID: 27660340
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Immunobiology of chronic inflammatory bowel diseases].
    Siegmund B; Zeitz M
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2657-60. PubMed ID: 17109275
    [No Abstract]   [Full Text] [Related]  

  • 57. On naivety of T cells in inflammatory bowel disease: a review.
    Smids C; Horjus Talabur Horje CS; Wahab PJ; Groenen MJ; Middendorp S; van Lochem EG
    Inflamm Bowel Dis; 2015 Jan; 21(1):167-72. PubMed ID: 25268637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation.
    Cader MZ; Kaser A
    Gut; 2013 Nov; 62(11):1653-64. PubMed ID: 24104886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. From airway inflammation to inflammatory bowel disease: eotaxin-1, a key regulator of intestinal inflammation.
    Adar T; Shteingart S; Ben Ya'acov A; Bar-Gil Shitrit A; Goldin E
    Clin Immunol; 2014 Jul; 153(1):199-208. PubMed ID: 24786916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response.
    Thompson-Chagoyán OC; Maldonado J; Gil A
    Clin Nutr; 2005 Jun; 24(3):339-52. PubMed ID: 15896420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.